Grenze International Journal of Engineering and Technology, June Issue

Machine Learning (ML) and Deep Learning (DL) in Healthcare and Pharmaceutical Innovation: Alzheimers Disease Diagnosis and Drug Discovery

Pragati Anil Dongare[1] and Deepak S. Khobragade[2]
[1-2]Datta Meghe college of Pharmacy, (Department of Pharmaceutical Sciences) DMIHER Wardha 442001 Maharashtra, India
Email: pragatidongare501@gmail.com, deepak.pharmacy@dmiher.edu.in

***Abstract*— Machine Learning (ML) together with Deep Learning (DL) function as vital technological tools which drive healthcare and pharmaceutical development through their ability to analyze complex biomedical data at scale. The growing amount of electronic health records, together with medical imaging, genomic databases, and clinical trial repositories, requires computational approaches which produce accurate predictions and clinical decision support. The research investigates all machine learning (ML) and deep learning (DL) applications which appear in healthcare and pharmaceutical development for neurodegenerative diseases including Alzheimer's disease. The healthcare industry experiences major improvements in disease detection through early stages because of two ML systems which combine deep learning with convolutional neural networks and recurrent neural networks. Transformer-based architectures for medical image analysis and patient risk assessment. The methods enable Alzheimer's disease diagnosis at an early stage through neuroimaging analysis and cognitive assessment modelling and biomarker-based prediction approaches. The system enables fast disease detection which enables medical professionals to start treatment without delay while they can watch the disease progression. Pharmaceutical research benefits from machine learning (ML) and deep learning (DL) because these technologies accelerate drug discovery and development through their ability to perform virtual screening, drug-target interaction prediction, toxicity evaluation, and pharmacokinetic and pharmacodynamic optimization. Researchers actively search for new treatment options to fight Alzheimer's disease. The combination of ML with DL, big data analytics, Internet of Medical Things platforms, and cloud-based infrastructures enables better patient monitoring through real-time surveillance. This helps create personalized treatment approaches. The new technologies have not solved the problem of clinical application because medical data remains unstructured and deep learning models stay difficult to interpret, and there are ethical problems, and medical professionals must adhere to established rules. The paper presents current advancements together with their main applications and challenges while it predicts future trends, which include explainable artificial intelligence and precision medicine to create reliable, scalable systems.**

***Index Terms*— Machine Learning, Deep Learning, Alzheimer's Disease, Neurodegenerative Disorders, Drug Discovery, Medical Imaging, Healthcare Analytics, Pharmaceutical Innovation.**

Grenze ID: 01.GIJET.12.2.498_22

I. INTRODUCTION

Digital technologies keep evolving at an unrelenting pace because data-driven systems now operate throughout numerous business sectors. The situation brought about a complete transformation which affected the development of healthcare and pharmaceutical sciences. The growing volume of electronic health records, together with medical imaging data, genomic information, clinical trial datasets, and real-world evidence, allows researchers to conduct smart data analysis. The complex organization and extensive dimensions and diverse nature of biomedical data create obstacles which standard statistical approaches and rule-based systems cannot overcome. Machine Learning (ML) and Deep Learning (DL) operate as essential computational tools. They enable users to find important data patterns. They produce precise predictions to support medical decision-making and pharmaceutical development. ML techniques enable systems to learn from data while they improve their performance without needing programming instructions, but DL employs multiple neural network layers to handle complex data which exists in unstructured and high-dimensional formats. [1] The analysis of medical images and disease prediction and biomarker detection has shown promising results through the use of advanced deep learning models which include convolutional neural networks, recurrent neural networks, and transformer-based architectures. The core technologies enable medical professionals to reach accurate diagnoses while they detect diseases during their initial stages, and they generate personalized treatment methods for each patient. Neurodegenerative illnesses, along with Alzheimer’s disease, present a major global health problem because they develop steadily, and research has not found any cures, and their occurrence continues to rise among older people. Medical professionals encounter difficulties when they attempt to identify Alzheimer's disease at its initial stages through their usual diagnostic methods [1,2].

Machine learning (ML) together with deep learning (DL) approaches have demonstrated strong potential to address this issue through their analysis of neuroimaging data, cognitive test results, and biological biomarkers which enable early and precise detection of problems. Pharmaceutical research benefits from ML and DL through their ability to speed up virtual screening and predict drug–target interactions, and assess toxicity, and improve pharmacokinetic and pharmacodynamic properties. This helps scientists find new therapeutic candidates for Alzheimer’s disease. The paper presents machine learning (ML) and deep learning (DL) as healthcare and pharmaceutical innovation game changers through its analysis of Alzheimer's disease applications and system architectures, and future research opportunities, while addressing current challenges with data quality and interpretability, and regulatory compliance [5].



Fig: 1

Fig: 2

II. LITERATURE REVIEW

In recent years, there has been a lot of research on how to use Machine Learning (ML) and Deep Learning (DL) techniques in healthcare and pharmaceutical sciences. This is because there are now big biological datasets and computers that can do more work. Early research predominantly utilized conventional machine learning techniques, including support vector machines (SVM), decision trees, k-nearest neighbors, and random forest models, for disease categorization and risk prediction utilizing structured clinical data. These methods worked moderately well for diagnosing and predicting diseases, but they had problems with manual feature extraction and scaling. Researchers have been looking more and more at neural network–based designs to get around these problems since DL came out. Convolutional neural networks (CNNs) are frequently used in medical imaging, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) [4].

They are very good at finding diseases and classifying tissues. Multiple studies have indicated enhanced efficacy of CNN- based models compared to traditional ML methods for the earlydetection of Alzheimer's disease by automated processing of neuroimaging data. Longitudinal clinical and cognitive datasets have also been used with recurrent neural networks (RNNs) and long short-term memory (LSTM) networks to model how diseases become worse and how patients do. In pharmaceutical research, machine learning (ML) and deep learning (DL) methods have been widely examined for the discovery and development of drugs. Previous research underscores the efficacy of ML-based quantitative structure–activity connection models and DL-driven virtual screening methodologies in the efficient identification of new therapeutic candidates. Graph neural networks and deep autoencoders have been utilized to forecast drug–target interactions, toxicity profiles, and pharmacokinetic features, markedly decreasing time and expenses in the first phases of drug development [6].
Machine learning models together with deep learning systems help scientists find new treatment targets for Alzheimer's disease while they also predict blood-brain barrier penetration and assess drug safety and effectiveness. The research findings show encouraging results but multiple studies have identified four common problems which include insufficient data availability, excessive data variability, models that lack interpretability, and regulatory obstacles that block scientific studies
[7]. The current research focus concentrates on three core areas which include explainable artificial intelligence, federated learning, and multimodal data integration to enhance clinical trust and real-world applicability. Machine learning together with deep learning systems have shown growing potential as vital tools for developing smart healthcare systems and pharmaceutical breakthroughs through their ability to solve complex diseases including Alzheimer's disease [3].

III. Materials and Methods

The section describes datasets together with system architecture and preprocessing techniques and machine learning, and deep learning models, and assessment metrics which serve healthcare and pharmaceutical domains with special focus on Alzheimer's disease research.

A. Sources of Data

The biomedical datasets arrived from public repositories, which also included verified datasets. The healthcare data collection included neuroimaging data which consisted of structural MRI scans and PET scans, and cognitive assessment results, and clinical biomarkers that relate to Alzheimer's disease. The pharmaceutical datasets consisted of three types, which included compound libraries, and drug-target interaction databases, and pharmacokinetics and toxicity datasets. All data were anonymised and followed ethical and data protection rules.

B. Preparing the Data

The raw data underwent pre-processing to verify its quality and maintain uniformity throughout the dataset. The process of feature extraction became more manageable after we normalized and scaled, and augmented the imaging data while also reducing the amount of noise present in the data. We cleaned the clinical and biomarker data to deal with missing values, standardized it, and encoded it when it was needed. The model achieved better performance through faster operations because principal component analysis helped with feature selection and dimensionality reduction.

C. The Framework of the Model

Our research team conducted a performance evaluation between machine learning models and deep learning models through a direct comparison. Our research team applied three traditional machine learning techniques which consisted of support vector machines, random forest, and logistic regression to analyze structured clinical data and biomarker information. The combination of convolutional neural networks with recurrent neural networks served as the solution for processing imaging data and high-dimensional datasets. The pharmaceutical analysis process used deep neural networks together with graph- based models to predict how drugs will interact with targets and their toxicity levels. This affects Alzheimer's disease treatment development [8].

D. Training and Evaluation

The research team used standard cross-validation techniques to divide their data into three separate sets, which included training data, validation data, and testing data. The models received their best hyperparameters along with regularization techniques which helped them avoid overfitting during training. The evaluation process used accuracy together with sensitivity, specificity, precision, recall, and area under the receiver operating characteristic curve as performance assessment criteria [9].

E. Tools and Implementation

Our team developed all models through Python-based frameworks which included TensorFlow, Keras, and Scikit-learn. Our team conducted system tests to evaluate the performance of graphics processing units which we used for accelerating model training and inference operations. The method provides a strong framework which enables testing of intelligent healthcare and pharmaceutical applications that use ML and DL for drug discovery and Alzheimer's disease diagnosis [10, 11].

TABLE I: MULTIPLE DATASETS FROM PUBLIC AND PROPRIETARY REPOSITORIES WERE USED

Dataset	Type	Purpose	Source
ADNI (Alzheimer's Disease Neuroimaging Initiative)	MRI, PET scans, cognitive scores	Early diagnosis, disease progression modeling	adni.loni.usc.edu
OASIS	Structural MRI	Brain imaging for AD and healthy controls	oasis-brains.org
Open Drug Discovery Platforms	Drug–target interactions, pharmacokinetics, toxicity data	Drug discovery and therapeutic candidate screening	ChEMBL, PubChem
Clinical Biomarker Data	Blood tests, CSF biomarkers	Disease prediction and patient stratification	Public clinical trial datasets

IV. RESULTS

Our research tested the proposed ML and DL architecture against healthcare and pharmaceutical datasets which focused on Alzheimer's disease diagnosis and drug discovery applications. We assessed various models through their performance metrics which included accuracy, sensitivity, specificity, precision, recall, F1-score, and the area under the ROC curve (AUC).



Fig. 3. Overall Workflow of ML/DL in Healthcare and Pharmaceutical Innovation



Fig 4. Alzheimer's Disease Diagnosis using ML/DL



Fig 5. ML/DL based Drug Discovery for Alzheimer's Therapeutics

A. Alzheimer's Disease Diagnosis

TABLE II: PERFORMANCE OF ML AND DL MODELS FOR AD DIAGNOSIS

Model	Accuracy (%)	Sensitivity (%)	Specificity (%)	AUC
SVM	85.2	83.1	87.0	0.89
Random Forest	87.5	85.4	89.1	0.91
Logistic Regression	81.3	79.0	83.5	0.86
CNN	93.4	92.0	94.5	0.97
RNN/LSTM	91.1	89.5	92.5	0.95



Fig. 4 ML and DL Models for Alzheimer Disease

Observations:
Deep learning models which include CNN and RNN/LSTM outperformed standard ML models in detecting Alzheimer's illness at its earliest stage. The analysis of neuroimaging data showed CNN achieved the highest accuracy together with AUC because it automatically extracted spatial information from MRI and PET datasets. The RNN/LSTM technique proved successful when it came to predicting long-term cognitive scores and estimating how the condition would evolve.

B. Pharmaceutical Applications

TABLE II: DRUG DISCOVERY MODEL PERFORMANCE

Task	Model	Accuracy (%)	Precision (%)	Recall (%)	F1-score
Drug–target prediction	Deep Neural Network	89.6	88.2	90.1	89.1
Toxicity prediction	Random Forest	85.4	84.0	86.3	85.1
Pharmacokinetics & ADME	Gradient Boosting	87.2	86.0	87.5	86.7



Fig. 5 ML and DL Models for Alzheimer Disease Applications

Observations:
The prediction of drug-target interactions for Alzheimer's treatments became accurate through the use of deep neural networks and graph-based models. ML-based toxicity and pharmacokinetic models cut down on false positives in the first stages of drug testing. The combination of chemical data with biological information, and clinical records, led to better prediction results.

C. Seeing how well the model works

The CNN-based models achieved the top AUC scores which exceeded 0.95 for AD classification according to the ROC Curves analysis. The confusion matrices revealed that patients with early-stage and late-stage AD both achieved high true positive rates. The Random Forest algorithm together with Gradient Boosting identified crucial biomarkers and chemical features, which aided in their analysis. The assessment system tracks disease development. It shows how well medical treatments work for patients.

D. Important Results

Deep learning models deliver better results than standard machine learning techniques when researchers analyze neuroimaging data with Alzheimer's disease clinical records that span multiple years. The drug development process benefits from ML and DL methods, which speed up various stages, including drug target interaction prediction, toxicity evaluation, and pharmacokinetic profiling. The combination of imaging data with clinical information and molecular data leads to improved model reliability. This supports better personalized treatment outcomes. The medical field needs explainable AI systems because of its current issues with data imbalance and interpretability problems.

V. Discussion

The research findings show that Machine Learning (ML) and Deep Learning (DL) systems provide major enhancements to diagnostic accuracy and prediction systems, which help develop better treatments for neurodegenerative diseases including Alzheimer's disease (AD). The analysis of neuroimaging and longitudinal cognitive data becomes more effective through DL models, which include CNNs and RNN/LSTM networks, than through traditional ML algorithms such as SVM, Random Forest, and Logistic Regression. DL models perform pattern detection at a higher level because they can automatically detect both spatial and temporal patterns. Traditional ML algorithms fail to identify. The research findings support previous studies which demonstrate CNNs perform well in detecting early-stage Alzheimer's disease and LSTM models show promise for predicting disease progression through patient data collected over time. The pharmaceutical industry uses ML and DL together to predict drug-target relationships and assess drug safety, and determine how drugs will move through the body. The search for potential Alzheimer's disease treatments became most successful through the combination of deep neural networks with graph-based models. The findings demonstrate that computational approaches enable scientists to shorten the initial drug development process while they reduce expenses and speed up the process. The model reached its highest level of reliability through the combination of multimodal datasets, which included imaging data, biomarker information, and chemical analysis results. The development of personalized treatment approaches received support from this method.

The study produced promising results which must now deal with various challenges. These exist in the present. These remain unsolved. Machine learning models face three primary obstacles when trying to generalize data because they must deal with diverse data types, and they lack big annotated datasets, and disease samples appear more often than control samples. Deep learning systems function as black boxes which prevents users from understanding their internal operational mechanisms. The medical field faces two main challenges because doctors struggle to use these models, and regulatory organizations must overcome obstacles when trying to approve them. You need to assess every privacy and ethical issue which emerges during the management of delicate health information. Researchers need to direct their future work toward developing explainable AI systems and federated learning techniques which protect privacy during collaborative work, and multi-omics data analysis with longitudinal information for better predictive results. The study results demonstrate how machine learning (ML) and deep learning (DL) technology enable healthcare and pharmaceutical innovation through scalable data-based systems which enable fast patient categorization, disease diagnosis, and accelerated drug development for Alzheimer's disease and other complex medical conditions.

VI. Future scope

ML and DL systems now deliver expanding value to healthcare operations and pharmaceutical research through their growing application. The tools achieve their full potential when used to detect and treat Alzheimer's disease (AD) through their current functionalities.

Medical applications require Explainable Artificial Intelligence (XAI) to build ML and DL models which provide understandable results. The field of research needs to focus on developing XAI frameworks. These show how models produce their results to help doctors understand the reasoning behind their Alzheimer's disease diagnosis and treatment suggestion systems.

Federated learning allows healthcare organizations to create models through collaboration while they keep patient information confidential. The approach solves three main problems which affect data privacy, data availability, and data variation to create models that can function across different environments.

Research in the future needs to merge imaging data with genomics, proteomics, metabolomics, and clinical information to create prediction models which will aid scientists in finding new biomarkers for Alzheimer's disease. Multimodal models offer complete understanding of disease processes and medical treatment possibilities. These tools allow us to find the best treatment options. They will produce the most successful results.

Machine learning and deep learning systems enable healthcare providers to develop personalized medical approaches through their ability to identify optimal medication dosages and predict patient responses to medical interventions. The approach will establish improved safety standards. This system will enable doctors to provide Pharmacological treatment for patients who have Alzheimer's disease and other complex medical conditions.

The combination of ML/DL technology with Internet of Medical Things (IoMT) devices enables continuous patient monitoring while it detects early signs of cognitive decline and delivers personalized therapeutic treatments for each individual. The system creates a healthcare network which works proactively to deliver medical services.

The drug discovery process reaches its peak speed because graph neural networks and reinforcement learning systems help researchers discover new compounds while predicting their blood-brain barrier penetration and their improved pharmacokinetic, and pharmacodynamic characteristics for Alzheimer's treatment.

The healthcare field, together with pharmaceutical sciences, will experience progress through ML and DL technology because these areas contain promising possibilities for future development. The system will generate improved diagnostic methods, which will become more understandable. The system offers tailored medical assistance to patients who require treatment for neurological disorders. This includes Alzheimer's disease.

VII. Conclusion

The research demonstrates how Machine Learning (ML) and Deep Learning (DL) systems enable healthcare and pharmaceutical sectors to create innovative solutions for Alzheimer's disease treatment. The research findings demonstrate that deep learning (DL) models, which include convolutional and recurrent neural networks, perform better than standard machine learning (ML) algorithms for early disease diagnosis and illness progression prediction, and neuroimaging data analysis. The models identify complex patterns, which exist throughout space and time to help people identify Alzheimer's patients more quickly while developing personalized treatment approaches for them.

The pharmaceutical industry uses ML and DL methods to speed up drug discovery through their ability to predict drug- target interactions and assess toxicity levels, and enhance drug pharmacokinetic and pharmacodynamic properties. The combination of multimodal information, which includes imaging data, clinical data, and genomic data, leads to more accurate models that support personalized medical treatment initiatives.

The healthcare sector has made significant progress but multiple challenges continue to block the complete implementation of clinical adoption practices. The system faces four major issues, which include the lack of enough annotated datasets, the presence of multiple data sources, complex models, and rigid regulatory standards. Scientists need to direct their upcoming studies toward explainable AI systems and federated learning approaches which protect privacy during collaboration. Multi-omics data integration boosts prediction performance and medical treatment reliability.

ML and DL systems provide healthcare and pharmaceutical science with a powerful, adaptable intelligent system which helps doctors achieve better patient results, and speed up drug discovery, and data-based medical decisions. The strategies examined in this work have the ability to improve early detection of Alzheimer's disease and other complicated diseases, which will lead to the development of future precision medicine solutions.

References

[1] G. Castellano, A. Esposito, E. Lella, G. Montanaro, and G. Vessio, “Automated detection of Alzheimer’s disease: a multi-modal approach with 3D MRI and amyloid PET,” Scientific Reports, vol. 14, no. 1, pp. 1–10, 2024. IJSCSEIT

[2] D. A. Arafa, H. E. D. Moustafa, H. A. Ali, A. M. T. Ali-Eldin, and S. F. Saraya, A deep learning framework for early diagnosis of Alzheimer’s disease on MRI images, Springer US, 2024. IJSCSEIT

[3] H. Alshamlan, A. Alwassel, A. Banafa, and L. Alsaleem, “Improving Alzheimer’s disease prediction with different machine learning approaches and feature selection techniques,” Diagnostics, vol. 14, no. 19, 2024. MDPI

[4] Saeed M., Alzheimer’s disease detection using deep learning and machine learning: a review, Artificial Intelligence Review, vol. 58, pp. 262, 2025. Springer Nature Link

[5] Y. Wang, S. Liu, A. G. Spiteri et al., “Understanding machine learning applications in dementia research and clinical practice: a review for biomedical scientists and clinicians,” Alzheimer’s Research & Therapy, vol. 16, 175, 2024. SpringerLink

[6] S. Mohsen, “Alzheimer’s disease detection using deep learning and machine learning: a review,” Artificial Intelligence Review, vol. 58, art. 262, 2025. OUCI

[7] "Machine learning-based virtual screening and its applications to Alzheimer's drug discovery: a review," Bentham Science Publishers, 2024. PubMed
[8] "Machine learning in Alzheimer's disease drug discovery and target identification," Elsevier Review, 2023. PubMed
[9] U. A. Wadighare and S. P. Deshmukh, "A review on artificial intelligence and machine learning used in pharmaceutical research," GSC Biological and Pharmaceutical Sciences, vol. 26, no. 1, pp. 191–198, 2024. GSC Online Press
[10] N. Bini Balakrishnan, P. S. Sreeja, and J. Jose Panackal, Alzheimers Disease Diagnosis using Machine Learning: A Review, arXiv:2304.09178, 2023. arXiv
[11] S. Kumar, I. Oh, S. Schindler et al., Machine learning for modeling the progression of Alzheimer disease dementia using clinical data: a systematic literature review, arXiv:2108.04174, 2021. arXiv